Answers are grounded in this paper and cite their sources.
Background Microglial dysfunction is critically involved in Alzheimer’s disease (AD) progression, yet microglia-derived molecular signatures that reflect neuropathological progression and reveal potential therapeutic targets remain incompletely understood. This study aimed to establish a microglia-based risk score model for predicting AD progression and to validate the functional role of model genes in microglial activation. Methods Single-cell RNA sequencing datasets from AD brain tissues were analyzed to characterize disease-associated microglial subpopulations. Weighted gene co-expression network analysis (WGCNA) was performed to identify gene modules associated with Braak neuropathological stages. Microglial marker genes from advanced stage were integrated with Braak-related module genes to identify candidate genes. A least absolute shrinkage and selection operator (LASSO) regression model was constructed to generate a microglia-derived risk score. The relationship between risk score and immune microenvironment features was evaluated. FKBP5 was selected for experimental validation using an Aβ1-42-induced BV2 microglial activation model, followed by molecular docking to explore potential FKBP5-targeting compounds. Results Single-cell transcriptomic analysis revealed neuropathological progression in microglial states during AD progression, with enrichment of activated and immune-related microglial signatures. Integration of microglial markers and Braak-associated WGCNA modules identified 25 overlapping genes involved in immune regulation and microglial function. The LASSO-derived risk score effectively reflected AD progression and was positively associated with microglial activation and immune remodeling. Among the candidate genes, FKBP5 showed increased expression during AD progression and was closely correlated with activated microglial phenotypes. In vitro experiments demonstrated that Aβ1-42 stimulation significantly increased FKBP5 expression and promoted microglial activation via NF-κB signaling, whereas FKBP5 inhibition attenuated activation-related cytokine expression. Molecular docking analysis further suggested potential FKBP5-interacting compounds including Apatinib, Eslicarbazepine acetate, Cefadroxil, Thioisonicotinamide, and Atropine. These computationally predicted interactions warrant further experimental validation to explore their potential pharmacological relevance. Conclusion We developed a microglia-derived molecular risk score that reflects AD neuropathological progression and immune microenvironment remodeling. FKBP5 was identified as a critical regulator of microglial activation and represents a potential therapeutic target for modulating neuroinflammation in AD. These findings provide new insights into microglia-mediated AD progression and establish a framework for integrating single-cell transcriptomics with experimental validation for biomarker and target discovery.
No takes yet. Share an insight, caveat, or question.
Xie et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: